Elekta (OTCMKTS:EKTAY) Sees Strong Trading Volume – Still a Buy?

Shares of Elekta AB (OTCMKTS:EKTAY) saw unusually-high trading volume on Thursday . Approximately 6,765 shares changed hands during trading, an increase of 125% from the previous session’s volume of 3,000 shares.The stock last traded at $5.76 and had previously closed at $5.83.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Elekta Stock Down 1.2%

The company has a fifty day moving average of $5.14 and a 200 day moving average of $5.72. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47. The company has a market cap of $2.12 billion, a P/E ratio of -36.00 and a beta of 1.01.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. The business had revenue of $521.00 million during the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%. On average, research analysts anticipate that Elekta AB will post 0.43 earnings per share for the current fiscal year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.